Mylan Appeals Dismissal Of Prilosec Antitrust Claims
Three years after a court ruled that Mylan Laboratories Inc. did not infringe patents for AstraZeneca AB's heartburn drug Prilosec, Mylan is taking its allegations that AstraZeneca violated antitrust law by...To view the full article, register now.
Already a subscriber? Click here to view full article